Document Detail


Zoledronic acid in metastatic bone disease: an audit based discussion.
MedLine Citation:
PMID:  22338405     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Metastatic bone disease is a common problem in patients with advanced cancer causing significant morbidity and poor quality of life. Effective and less toxic treatments, like bisphophonates, can reduce morbidity in such cases.
OBJECTIVES: The objectives of this study were to determine whether Zoledronic acid was administered in accordance with current recommendations for its prescribing and to produce protocols for improved patient outcomes.
METHODS: The study was a retrospective audit of 39 consecutive patients with metastatic bone disease secondary to solid tumours who were treated with Zoledronic acid. The records were analysed to establish the administered dose of Zoledronic acid relative to creatinine clearance. The standards for Zoledronic acid therapy were defined from best practice guidelines.
RESULTS: The commonest diagnosis in patients receiving Zoledronic acid was carcinoma prostate 19/39 (49%) followed by carcinoma breast 11/39 (28%), gastrointestinal malignancies 4/39 (10%) and renal cell carcinoma 3/39 (8%). Indications for therapy were metastatic bone disease alone 31 (79%), hypercalcaemia alone 0/39 (0%), metastatic bone disease with hypercalcaemia 5/39 (13%), and prevention of chemotherapy induced bone loss 1/39 (3%). The dose of Zoledronic acid was appropriate to the creatinine clearance in 25/39 (64%), inappropriate in 5/39 (13%) and unclear from the notes in 9/39 (23%).
CONCLUSIONS: Majority of patients received Zoledronic acid for the appropriate indications. The dose of Zoledronic acid was appropriate to serum creatinine clearance in a majority of patients. Poor documentation of data pertaining to Zoledronic acid treatment is observed which can potentially lead to major errors in prescribing. We recommend using a standard form to document each episode of therapy with Zoledronic acid.
Authors:
Raza Ali Akbar; S K Gosh; S Khalil; Sheikh Moeen ul Haq
Related Documents :
6287045 - A clinical study of 99mtechnetium dimercaptosuccinic acid uptake in obstructed kidneys:...
3985945 - Effect of ouabain on amino acid uptake by mouse ascites-tumour cells in the presence of...
11834205 - Proliferation of peripheral blood mononuclear cells causes increased expression of the ...
7395765 - Uptake and release of amino acids by normal and remnant kidneys: studies in the isolate...
6111555 - Effect of cerulenin on cellular autolytic activity and lipid metabolism during inhibiti...
186605 - Adrenocorticotropin. 49.1 synthesis and biological activity of [2-delta-aminovaleric ac...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of Ayub Medical College, Abbottabad : JAMC     Volume:  22     ISSN:  1025-9589     ISO Abbreviation:  J Ayub Med Coll Abbottabad     Publication Date:    2010 Jul-Sep
Date Detail:
Created Date:  2012-02-17     Completed Date:  2012-04-05     Revised Date:  2012-10-24    
Medline Journal Info:
Nlm Unique ID:  8910750     Medline TA:  J Ayub Med Coll Abbottabad     Country:  Pakistan    
Other Details:
Languages:  eng     Pagination:  5-7     Citation Subset:  IM    
Affiliation:
Department of Acute and General Medicine, Wansbeck General Hospital, Northumbria Healthcare NHS Foundation Trust, NE63 9JJ, United Kingdom. ali1334@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers / blood
Bone Density Conservation Agents / administration & dosage,  therapeutic use*
Bone Neoplasms / drug therapy*,  secondary*
Bone Resorption / prevention & control*
Bone and Bones / drug effects*,  metabolism
Calcium / blood,  therapeutic use
Creatinine / blood
Diphosphonates / administration & dosage,  therapeutic use*
Documentation
Female
Humans
Imidazoles / administration & dosage,  therapeutic use*
Male
Neoplasms / pathology*
Retrospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid; 60-27-5/Creatinine; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of hepatitis C in 2011.
Next Document:  Response rate of Pakistani children with acute lymphoblastic leukaemia to Medical Research Council a...